Prothena Corporation plc (NASDAQ:PRTA) Ratings Summary on May 17, 2018

May 17, 2018 - By Mary Markley

Prothena Corporation plc (NASDAQ:PRTA) Corporate Logo
During Q4 2017 the big money sentiment decreased to 1.18. That’s change of 0.47, from 2017Q3’s 1.65. 29 investors sold all, 32 reduced holdings as Prothena Corporation plc ratio worsened. 44 grew holdings while 28 funds took holdings. Funds hold 31.32 million shares thus 0.27% more from 2017Q3’s 31.24 million shares.
Prelude Capital Mgmt Llc invested in 0% or 98 shs. Hudson Bay Cap Mgmt Lp reported 0.04% of its capital in Prothena Corporation plc (NASDAQ:PRTA). State Common Retirement Fund has invested 0% in Prothena Corporation plc (NASDAQ:PRTA). Moreover, Checchi Cap Advisers Limited Co has 0.05% invested in Prothena Corporation plc (NASDAQ:PRTA) for 9,528 shs. Axa stated it has 0.02% of its capital in Prothena Corporation plc (NASDAQ:PRTA). Parallax Volatility Advisers Limited Partnership accumulated 5,922 shs or 0% of the stock. Moreover, Focused Wealth Mngmt has 0.07% invested in Prothena Corporation plc (NASDAQ:PRTA). Qs Investors Llc has invested 0% in Prothena Corporation plc (NASDAQ:PRTA). California Pub Employees Retirement Sys holds 0% in Prothena Corporation plc (NASDAQ:PRTA) or 63,000 shs. Carroll Associate Incorporated stated it has 0% of its capital in Prothena Corporation plc (NASDAQ:PRTA). Mufg Americas invested in 0% or 97 shs. Clearbridge Invs Limited Liability Company has invested 0% of its capital in Prothena Corporation plc (NASDAQ:PRTA). Morgan Stanley owns 156,519 shs or 0% of their US capital. Capital Fund Management Sa holds 0% or 8,800 shs in its capital. Century Companies Inc holds 33,377 shs or 0% of its capital.

Prothena Corporation plc (NASDAQ:PRTA) Ratings Coverage

In total 10 analysts cover Prothena Corp PLC (NASDAQ:PRTA). “Buy” rating has 3, “Sell” are 0, while 7 are “Hold”. (NASDAQ:PRTA) has 30% bullish analysts. 16 are the (NASDAQ:PRTA)’s ratings reports on May 17, 2018 according to StockzIntelligence Inc. On Tuesday, April 24 the firm has “Buy” rating by Nomura given. On Monday, April 23 the firm earned “Hold” rating by Oppenheimer. On Tuesday, April 24 the rating was downgraded by BTIG Research to “Neutral”. On Monday, November 20 the firm has “Neutral” rating given by Wedbush. In Thursday, February 15 report Cantor Fitzgerald maintained it with “Buy” rating and $65.0 target. In Monday, December 4 report Oppenheimer maintained it with “Buy” rating and $70.0 target. On Thursday, April 5 the stock of Prothena Corporation plc (NASDAQ:PRTA) earned “Overweight” rating by Barclays Capital. On Tuesday, March 20 the company was maintained by Cantor Fitzgerald. On Tuesday, April 24 Deutsche Bank maintained the shares of PRTA in report with “Buy” rating. On Monday, April 23 the firm earned “Hold” rating by RBC Capital Markets. Listed here are Prothena Corporation plc (NASDAQ:PRTA) PTs and latest ratings.

24/04/2018 Broker: Nomura Old Rating: Buy New Rating: Buy Old Target: $87 New Target: $19 Maintain
24/04/2018 Broker: Deutsche Bank Old Rating: Buy New Rating: Buy Old Target: $78 New Target: $16 Maintain
24/04/2018 Broker: BTIG Research Old Rating: Buy New Rating: Neutral Old Target: $77 Downgrade
24/04/2018 Broker: Cantor Fitzgerald Old Rating: Overweight New Rating: Overweight Old Target: $69 New Target: $14 Maintain
23/04/2018 Broker: Oppenheimer Rating: Hold Downgrade
23/04/2018 Broker: RBC Capital Markets Rating: Hold Downgrade
23/04/2018 Broker: Barclays Capital Rating: Hold Downgrade
23/04/2018 Broker: Jefferies Old Rating: Buy New Rating: Hold Old Target: $100 Downgrade
23/04/2018 Broker: Evercore Old Rating: Outperform New Rating: In-Line Old Target: $76 New Target: $12 Downgrade
05/04/2018 Broker: Barclays Capital Old Rating: Overweight New Rating: Overweight Old Target: $70 New Target: $50 Maintain

Ticker’s shares touched $16.31 during the last trading session after 0.73% change.Currently Prothena Corporation plc is downtrending after 31.00% change in last May 17, 2017. PRTA has also 378,815 shares volume. The stock underperformed the S&P 500 by 42.55%.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion.The firm is worth $649.50 million. It is developing antibody product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating ParkinsonÂ’s disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development.Currently it has negative earnings. The firm has a license, development, and commercialization agreement with F.

For more Prothena Corporation plc (NASDAQ:PRTA) news brought out briefly go to: Digitaljournal.com, Seekingalpha.com, Globenewswire.com, Seekingalpha.com or Nasdaq.com. The titles are as follows: “NASDAQ:PRTA Shareholder Notice: Investigation over Possible Violations of Securities Laws by Prothena Corporation …” brought out on May 08, 2018, “Prothena: A Compelling Bounce Play To At Least $15 And Not Unrealistic Buyout Target” on April 25, 2018, “Prothena to Report First Quarter 2018 Financial Results on May 8” with a publish date: May 01, 2018, “Prothena: What Now?” and the last “Prothena Reports First Quarter 2018 Financial Results and Provides R&D Update” with publication date: May 08, 2018.

Prothena Corporation plc (NASDAQ:PRTA) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.